ID   CHIP_HUMAN              Reviewed;         303 AA.
AC   Q9UNE7; A2IDB9; O60526; Q969U2; Q9HBT1;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=E3 ubiquitin-protein ligase CHIP {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000269|PubMed:11557750, ECO:0000269|PubMed:15466472};
DE   AltName: Full=Antigen NY-CO-7 {ECO:0000303|PubMed:9610721};
DE   AltName: Full=CLL-associated antigen KW-8 {ECO:0000303|PubMed:12200376};
DE   AltName: Full=Carboxy terminus of Hsp70-interacting protein {ECO:0000303|PubMed:10330192};
DE   AltName: Full=RING-type E3 ubiquitin transferase CHIP {ECO:0000305};
DE   AltName: Full=STIP1 homology and U box-containing protein 1 {ECO:0000312|HGNC:HGNC:11427};
GN   Name=STUB1 {ECO:0000312|HGNC:HGNC:11427};
GN   Synonyms=CHIP {ECO:0000303|PubMed:10330192};
GN   ORFNames=PP1131 {ECO:0000312|EMBL:AAG17211.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND IDENTIFICATION AS
RP   TUMOR-ASSOCIATED ANTIGEN.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9610721;
RX   DOI=10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.0.CO;2-P;
RA   Scanlan M.J., Chen Y.-T., Williamson B., Gure A.O., Stockert E.,
RA   Gordan J.D., Tuereci O., Sahin U., Pfreundschuh M., Old L.J.;
RT   "Characterization of human colon cancer antigens recognized by
RT   autologous antibodies.";
RL   Int. J. Cancer 76:652-658(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   HSPA8 AND HSPA1A, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=10330192; DOI=10.1128/MCB.19.6.4535;
RA   Ballinger C.A., Connell P., Wu Y., Hu Z., Thompson L.J., Yin L.-Y.,
RA   Patterson C.;
RT   "Identification of CHIP, a novel tetratricopeptide repeat-containing
RT   protein that interacts with heat shock proteins and negatively
RT   regulates chaperone functions.";
RL   Mol. Cell. Biol. 19:4535-4545(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND IDENTIFICATION AS
RP   TUMOR-ASSOCIATED ANTIGEN.
RX   PubMed=12200376; DOI=10.1182/blood-2002-02-0513;
RA   Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J.,
RA   Chessia M., Barrett P., Gribben J.G.;
RT   "Identification of tumor-associated antigens in chronic lymphocytic
RT   leukemia by SEREX.";
RL   Blood 100:2123-2131(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 13-30; 56-66; 86-119; 129-140; 155-167; 235-241;
RP   256-263 AND 273-287, PHOSPHORYLATION AT SER-19, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=11435423; DOI=10.1074/jbc.M102755200;
RA   Hatakeyama S., Yada M., Matsumoto M., Ishida N., Nakayama K.I.;
RT   "U box proteins as a new family of ubiquitin-protein ligases.";
RL   J. Biol. Chem. 276:33111-33120(2001).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND INTERACTION WITH HSPA8;
RP   UBE2D1; UBE2D2 AND UBE2D3.
RX   PubMed=11557750; DOI=10.1074/jbc.M101968200;
RA   Jiang J., Ballinger C.A., Wu Y., Dai Q., Cyr D.M., Hoehfeld J.,
RA   Patterson C.;
RT   "CHIP is a U-box-dependent E3 ubiquitin ligase: identification of
RT   Hsc70 as a target for ubiquitylation.";
RL   J. Biol. Chem. 276:42938-42944(2001).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HSP90.
RX   PubMed=11146632; DOI=10.1038/35050618;
RA   Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J.,
RA   Hoehfeld J., Patterson C.;
RT   "The co-chaperone CHIP regulates protein triage decisions mediated by
RT   heat-shock proteins.";
RL   Nat. Cell Biol. 3:93-96(2001).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=15466472; DOI=10.1074/jbc.M406926200;
RA   Peng H.M., Morishima Y., Jenkins G.J., Dunbar A.Y., Lau M.,
RA   Patterson C., Pratt W.B., Osawa Y.;
RT   "Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a
RT   chaperone-dependent E3 ligase.";
RL   J. Biol. Chem. 279:52970-52977(2004).
RN   [14]
RP   INTERACTION WITH HSPA1A AND HSPBP1.
RX   PubMed=15215316; DOI=10.1091/mbc.E04-04-0293;
RA   Alberti S., Boehse K., Arndt V., Schmitz A., Hoehfeld J.;
RT   "The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and
RT   stimulates the maturation of the cystic fibrosis transmembrane
RT   conductance regulator.";
RL   Mol. Biol. Cell 15:4003-4010(2004).
RN   [15]
RP   INTERACTION WITH BAG2.
RX   PubMed=16169850; DOI=10.1074/jbc.M507986200;
RA   Dai Q., Qian S.B., Li H.-H., McDonough H., Borchers C., Huang D.,
RA   Takayama S., Younger J.M., Ren H.Y., Cyr D.M., Patterson C.;
RT   "Regulation of the cytoplasmic quality control protein degradation
RT   pathway by BAG2.";
RL   J. Biol. Chem. 280:38673-38681(2005).
RN   [16]
RP   INTERACTION WITH UBE2N AND UBE2V1.
RX   PubMed=16307917; DOI=10.1016/j.molcel.2005.09.023;
RA   Zhang M., Windheim M., Roe S.M., Peggie M., Cohen P., Prodromou C.,
RA   Pearl L.H.;
RT   "Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3
RT   ubiquitin ligase and a CHIP-Ubc13-Uev1a complex.";
RL   Mol. Cell 20:525-538(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   POLYUBIQUITINATION AT LYS-22; LYS-221 AND LYS-255, AND DOMAIN TPR.
RX   PubMed=18042044; DOI=10.1042/BJ20071338;
RA   Windheim M., Peggie M., Cohen P.;
RT   "Two different classes of E2 ubiquitin-conjugating enzymes are
RT   required for the mono-ubiquitination of proteins and elongation by
RT   polyubiquitin chains with a specific topology.";
RL   Biochem. J. 409:723-729(2008).
RN   [19]
RP   INTERACTION WITH MKKS.
RX   PubMed=18094050; DOI=10.1091/mbc.E07-07-0631;
RA   Hirayama S., Yamazaki Y., Kitamura A., Oda Y., Morito D., Okawa K.,
RA   Kimura H., Cyr D.M., Kubota H., Nagata K.;
RT   "MKKS is a centrosome-shuttling protein degraded by disease-causing
RT   mutations via CHIP-mediated ubiquitination.";
RL   Mol. Biol. Cell 19:899-911(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-23 AND SER-273,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [23]
RP   FUNCTION.
RX   PubMed=19103148; DOI=10.1016/j.abb.2008.12.001;
RA   Pabarcus M.K., Hoe N., Sadeghi S., Patterson C., Wiertz E.,
RA   Correia M.A.;
RT   "CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor
RT   receptor, AMFR) and CHIP E3 ligases.";
RL   Arch. Biochem. Biophys. 483:66-74(2009).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH POLB.
RX   PubMed=19713937; DOI=10.1038/emboj.2009.243;
RA   Parsons J.L., Tait P.S., Finch D., Dianova I.I., Edelmann M.J.,
RA   Khoronenkova S.V., Kessler B.M., Sharma R.A., McKenna W.G.,
RA   Dianov G.L.;
RT   "Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.";
RL   EMBO J. 28:3207-3215(2009).
RN   [25]
RP   INTERACTION WITH DYX1C1.
RX   PubMed=19423554; DOI=10.1093/hmg/ddp215;
RA   Massinen S., Tammimies K., Tapia-Paez I., Matsson H., Hokkanen M.E.,
RA   Soederberg O., Landegren U., Castren E., Gustafsson J.A., Treuter E.,
RA   Kere J.;
RT   "Functional interaction of DYX1C1 with estrogen receptors suggests
RT   involvement of hormonal pathways in dyslexia.";
RL   Hum. Mol. Genet. 18:2802-2812(2009).
RN   [26]
RP   FUNCTION.
RX   PubMed=19567782; DOI=10.1158/1541-7786.MCR-08-0582;
RA   Annamalai B., Liu X., Gopal U., Isaacs J.S.;
RT   "Hsp90 is an essential regulator of EphA2 receptor stability and
RT   signaling: implications for cancer cell migration and metastasis.";
RL   Mol. Cancer Res. 7:1021-1032(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19 AND SER-273, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19 AND SER-23, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   INTERACTION WITH DNAJB6.
RX   PubMed=22366786; DOI=10.1038/ng.1103;
RA   Sarparanta J., Jonson P.H., Golzio C., Sandell S., Luque H.,
RA   Screen M., McDonald K., Stajich J.M., Mahjneh I., Vihola A.,
RA   Raheem O., Penttila S., Lehtinen S., Huovinen S., Palmio J., Tasca G.,
RA   Ricci E., Hackman P., Hauser M., Katsanis N., Udd B.;
RT   "Mutations affecting the cytoplasmic functions of the co-chaperone
RT   DNAJB6 cause limb-girdle muscular dystrophy.";
RL   Nat. Genet. 44:450-455(2012).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [34]
RP   UBIQUITINATION AT LYS-2.
RX   PubMed=23560854; DOI=10.1042/BJ20130244;
RA   Tatham M.H., Plechanovova A., Jaffray E.G., Salmen H., Hay R.T.;
RT   "Ube2W conjugates ubiquitin to alpha-amino groups of protein N-
RT   termini.";
RL   Biochem. J. 453:137-145(2013).
RN   [35]
RP   FUNCTION, INDUCTION, INTERACTION WITH FOXP3, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LYS-30 AND HIS-260.
RX   PubMed=23973223; DOI=10.1016/j.immuni.2013.08.006;
RA   Chen Z., Barbi J., Bu S., Yang H.Y., Li Z., Gao Y., Jinasena D.,
RA   Fu J., Lin F., Chen C., Zhang J., Yu N., Li X., Shan Z., Nie J.,
RA   Gao Z., Tian H., Li Y., Yao Z., Zheng Y., Park B.V., Pan Z., Zhang J.,
RA   Dang E., Li Z., Wang H., Luo W., Li L., Semenza G.L., Zheng S.G.,
RA   Loser K., Tsun A., Greene M.I., Pardoll D.M., Pan F., Li B.;
RT   "The ubiquitin ligase Stub1 negatively modulates regulatory T cell
RT   suppressive activity by promoting degradation of the transcription
RT   factor Foxp3.";
RL   Immunity 39:272-285(2013).
RN   [36]
RP   FUNCTION, INTERACTION WITH HSPA8, AND MUTAGENESIS OF PRO-269.
RX   PubMed=23990462; DOI=10.1074/jbc.M113.479345;
RA   Matsumura Y., Sakai J., Skach W.R.;
RT   "Endoplasmic reticulum protein quality control is determined by
RT   cooperative interactions between Hsp/c70 protein and the CHIP E3
RT   ligase.";
RL   J. Biol. Chem. 288:31069-31079(2013).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-23; SER-25 AND
RP   SER-149, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH SMAD3; HSPA1A; HSPA1B; HSP90AA1 AND
RP   HSP90AB1.
RX   PubMed=24613385; DOI=10.1016/j.bbrc.2014.02.124;
RA   Shang Y., Xu X., Duan X., Guo J., Wang Y., Ren F., He D., Chang Z.;
RT   "Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through
RT   CHIP/Stub1.";
RL   Biochem. Biophys. Res. Commun. 446:387-392(2014).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [41]
RP   INTERACTION WITH FLCN AND HSP90AA1.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S.,
RA   Marston Linehan W., Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and
RT   enhance drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [42]
RP   FUNCTION, AND INTERACTION WITH HSPA1A; HSPA1B AND HSPA8.
RX   PubMed=27708256; DOI=10.1038/ncomms12882;
RA   Seo J.H., Park J.H., Lee E.J., Vo T.T., Choi H., Kim J.Y., Jang J.K.,
RA   Wee H.J., Lee H.S., Jang S.H., Park Z.Y., Jeong J., Lee K.J.,
RA   Seok S.H., Park J.Y., Lee B.J., Lee M.N., Oh G.T., Kim K.W.;
RT   "ARD1-mediated Hsp70 acetylation balances stress-induced protein
RT   refolding and degradation.";
RL   Nat. Commun. 7:12882-12882(2016).
RN   [43]
RP   VARIANTS SCAR16 ILE-130; CYS-147; PHE-165 AND THR-236, AND INVOLVEMENT
RP   IN SCAR16.
RX   PubMed=24312598; DOI=10.1371/journal.pone.0081884;
RA   Shi Y., Wang J., Li J.D., Ren H., Guan W., He M., Yan W., Zhou Y.,
RA   Hu Z., Zhang J., Xiao J., Su Z., Dai M., Wang J., Jiang H., Guo J.,
RA   Zhou Y., Zhang F., Li N., Du J., Xu Q., Hu Y., Pan Q., Shen L.,
RA   Wang G., Xia K., Zhang Z., Tang B.;
RT   "Identification of CHIP as a novel causative gene for autosomal
RT   recessive cerebellar ataxia.";
RL   PLoS ONE 8:E81884-E81884(2013).
RN   [44]
RP   VARIANT SCAR16 MET-246.
RX   PubMed=24113144; DOI=10.1093/hmg/ddt497;
RA   Shi C.H., Schisler J.C., Rubel C.E., Tan S., Song B., McDonough H.,
RA   Xu L., Portbury A.L., Mao C.Y., True C., Wang R.H., Wang Q.Z.,
RA   Sun S.L., Seminara S.B., Patterson C., Xu Y.M.;
RT   "Ataxia and hypogonadism caused by the loss of ubiquitin ligase
RT   activity of the U box protein CHIP.";
RL   Hum. Mol. Genet. 23:1013-1024(2014).
RN   [45]
RP   VARIANTS SCAR16 ASP-79; THR-79; VAL-123 AND THR-240.
RX   PubMed=24742043; DOI=10.1186/1750-1172-9-57;
RA   Synofzik M., Schuele R., Schulze M., Gburek-Augustat J., Schweizer R.,
RA   Schirmacher A., Kraegeloh-Mann I., Gonzalez M., Young P., Zuechner S.,
RA   Schoels L., Bauer P.;
RT   "Phenotype and frequency of STUB1 mutations: next-generation
RT   screenings in Caucasian ataxia and spastic paraplegia cohorts.";
RL   Orphanet J. Rare Dis. 9:57-64(2014).
RN   [46]
RP   VARIANT SCAR16 GLN-145.
RX   PubMed=24719489; DOI=10.1212/WNL.0000000000000416;
RA   Depondt C., Donatello S., Simonis N., Rai M., van Heurck R.,
RA   Abramowicz M., D'Hooghe M., Pandolfo M.;
RT   "Autosomal recessive cerebellar ataxia of adult onset due to STUB1
RT   mutations.";
RL   Neurology 82:1749-1750(2014).
RN   [47]
RP   VARIANTS SCAR16 LYS-28; SER-65 AND MET-246, AND CHARACTERIZATION OF
RP   VARIANTS SCAR16 LYS-28; SER-65 AND MET-246.
RX   PubMed=25258038; DOI=10.1186/s13023-014-0146-0;
RA   Heimdal K., Sanchez-Guixe M., Aukrust I., Bollerslev J., Bruland O.,
RA   Jablonski G.E., Erichsen A.K., Gude E., Koht J.A., Erdal S.,
RA   Fiskerstrand T., Haukanes B.I., Boman H., Bjoerkhaug L.,
RA   Tallaksen C.M., Knappskog P.M., Johansson S.;
RT   "STUB1 mutations in autosomal recessive ataxias - evidence for
RT   mutation-specific clinical heterogeneity.";
RL   Orphanet J. Rare Dis. 9:146-146(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which targets misfolded
CC       chaperone substrates towards proteasomal degradation. Collaborates
CC       with ATXN3 in the degradation of misfolded chaperone substrates:
CC       ATXN3 restricting the length of ubiquitin chain attached to
CC       STUB1/CHIP substrates and preventing further chain extension.
CC       Ubiquitinates NOS1 in concert with Hsp70 and Hsp40. Modulates the
CC       activity of several chaperone complexes, including Hsp70, Hsc70
CC       and Hsp90. Mediates transfer of non-canonical short ubiquitin
CC       chains to HSPA8 that have no effect on HSPA8 degradation. Mediates
CC       polyubiquitination of DNA polymerase beta (POLB) at 'Lys-41',
CC       'Lys-61' and 'Lys-81', thereby playing a role in base-excision
CC       repair: catalyzes polyubiquitination by amplifying the HUWE1/ARF-
CC       BP1-dependent monoubiquitination and leading to POLB-degradation
CC       by the proteasome. Mediates polyubiquitination of CYP3A4.
CC       Ubiquitinates EPHA2 and may regulate the receptor stability and
CC       activity through proteasomal degradation. Acts as a co-chaperone
CC       for HSPA1A and HSPA1B chaperone proteins and promotes ubiquitin-
CC       mediated protein degradation (PubMed:27708256). Negatively
CC       regulates the suppressive function of regulatory T-cells (Treg)
CC       during inflammation by mediating the ubiquitination and
CC       degradation of FOXP3 in a HSPA1A/B-dependent manner
CC       (PubMed:23973223). Negatively regulates TGF-beta signaling by
CC       modulating the basal level of SMAD3 via ubiquitin-mediated
CC       degradation (PubMed:24613385). {ECO:0000269|PubMed:10330192,
CC       ECO:0000269|PubMed:11146632, ECO:0000269|PubMed:11557750,
CC       ECO:0000269|PubMed:15466472, ECO:0000269|PubMed:19103148,
CC       ECO:0000269|PubMed:19567782, ECO:0000269|PubMed:19713937,
CC       ECO:0000269|PubMed:23973223, ECO:0000269|PubMed:23990462,
CC       ECO:0000269|PubMed:24613385}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:11557750,
CC       ECO:0000269|PubMed:15466472}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:11557750, ECO:0000269|PubMed:15466472}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with BAG2
CC       (PubMed:16169850). Interacts with E2 ubiquitin conjugating enzymes
CC       UBE2D1, UBE2D2 and UBE2D3 (PubMed:11557750). Detected in a ternary
CC       complex containing STUB1, HSPA1A and HSPBP1 (PubMed:15215316).
CC       Interacts with MKKS (PubMed:18094050). Interacts with DYX1C1
CC       (PubMed:19423554). Interacts with POLB (PubMed:19713937).
CC       Interacts (when monoubiquitinated) with ATXN3. Interacts with
CC       UBE2W. Interacts (via the U-box domain) with the UBE2V2-UBE2N
CC       heterodimer; the complex has a specific 'Lys-63'-linked
CC       polyubiquitination activity (By similarity). Interacts with DNAJB6
CC       (PubMed:22366786). Interacts with FOXP3 (PubMed:23973223).
CC       Interacts with FLCN (PubMed:27353360). Interacts with HSP90AA1
CC       (PubMed:27353360, PubMed:24613385). Interacts with HSP90
CC       (PubMed:11146632). Interacts with UBE2N and UBE2V1
CC       (PubMed:16307917). Interacts (via TPR repeats) with the C-terminal
CC       domain of HSPA1A (PubMed:10330192). Interacts with the non-
CC       acetylated form of HSPA1A and HSPA1B (PubMed:27708256). Interacts
CC       (via TPR repeats) with the C-terminal domain of HSPA8
CC       (PubMed:10330192, PubMed:11557750, PubMed:23990462,
CC       PubMed:27708256). Interacts with SMAD3 and HSP90AB1
CC       (PubMed:24613385). {ECO:0000250|UniProtKB:Q9WUD1,
CC       ECO:0000269|PubMed:10330192, ECO:0000269|PubMed:11146632,
CC       ECO:0000269|PubMed:11557750, ECO:0000269|PubMed:15215316,
CC       ECO:0000269|PubMed:16169850, ECO:0000269|PubMed:16307917,
CC       ECO:0000269|PubMed:18094050, ECO:0000269|PubMed:19423554,
CC       ECO:0000269|PubMed:19713937, ECO:0000269|PubMed:22366786,
CC       ECO:0000269|PubMed:23973223, ECO:0000269|PubMed:23990462,
CC       ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:27353360,
CC       ECO:0000269|PubMed:27708256}.
CC   -!- INTERACTION:
CC       A8K1F4:-; NbExp=2; IntAct=EBI-357085, EBI-9357094;
CC       Q96AP0:ACD; NbExp=2; IntAct=EBI-357085, EBI-717666;
CC       Q86WG3:ATCAY; NbExp=4; IntAct=EBI-357085, EBI-1783328;
CC       Q99933:BAG1; NbExp=2; IntAct=EBI-357085, EBI-1030678;
CC       O95816:BAG2; NbExp=4; IntAct=EBI-357085, EBI-355275;
CC       O95817:BAG3; NbExp=3; IntAct=EBI-357085, EBI-747185;
CC       Q9NRJ3:CCL28; NbExp=3; IntAct=EBI-357085, EBI-7783254;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-357085, EBI-297353;
CC       Q9BZS1:FOXP3; NbExp=7; IntAct=EBI-357085, EBI-983719;
CC       P07900:HSP90AA1; NbExp=9; IntAct=EBI-357085, EBI-296047;
CC       P08238:HSP90AB1; NbExp=5; IntAct=EBI-357085, EBI-352572;
CC       P08107:HSPA1B; NbExp=5; IntAct=EBI-357085, EBI-629985;
CC       P11142:HSPA8; NbExp=5; IntAct=EBI-357085, EBI-351896;
CC       Q9Y2U5:MAP3K2; NbExp=9; IntAct=EBI-357085, EBI-357393;
CC       P10636:MAPT; NbExp=2; IntAct=EBI-357085, EBI-366182;
CC       Q96PB7:OLFM3; NbExp=3; IntAct=EBI-357085, EBI-10292253;
CC       Q9BVN2:RUSC1; NbExp=3; IntAct=EBI-357085, EBI-6257312;
CC       Q99757:TXN2; NbExp=3; IntAct=EBI-357085, EBI-2932492;
CC       P61088:UBE2N; NbExp=5; IntAct=EBI-357085, EBI-1052908;
CC       Q7Z7E8:UBE2Q1; NbExp=3; IntAct=EBI-357085, EBI-1783287;
CC       P12504:vif (xeno); NbExp=2; IntAct=EBI-357085, EBI-779991;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10330192,
CC       ECO:0000269|PubMed:23973223}. Nucleus
CC       {ECO:0000269|PubMed:23973223}. Note=Translocates to the nucleus in
CC       response to inflammatory signals in regulatory T-cells (Treg).
CC       {ECO:0000269|PubMed:23973223}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UNE7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UNE7-2; Sequence=VSP_015947;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle, heart,
CC       pancreas, brain and placenta. Detected in kidney, liver and lung.
CC       {ECO:0000269|PubMed:10330192, ECO:0000269|PubMed:11435423}.
CC   -!- INDUCTION: Up-regulated by inflammatory signals in regulatory T-
CC       cells (Treg). {ECO:0000269|PubMed:23973223}.
CC   -!- DOMAIN: The U-box domain is required for the ubiquitin protein
CC       ligase activity. {ECO:0000250|UniProtKB:Q9WUD1}.
CC   -!- DOMAIN: The TPR domain is essential for ubiquitination mediated by
CC       UBE2D1. {ECO:0000269|PubMed:18042044}.
CC   -!- PTM: Monoubiquitinated at Lys-2 following cell stress by UBE2W,
CC       promoting the interaction with ATXN3 (By similarity). Auto-
CC       ubiquitinated; mediated by UBE2D1 and UBE2D2. {ECO:0000250,
CC       ECO:0000269|PubMed:18042044, ECO:0000269|PubMed:23560854}.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 16 (SCAR16)
CC       [MIM:615768]: Spinocerebellar ataxia defines a clinically and
CC       genetically heterogeneous group of cerebellar disorders. Patients
CC       show progressive incoordination of gait and often poor
CC       coordination of hands, speech and eye movements, due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR16 is characterized by truncal and
CC       limb ataxia resulting in gait instability. Additionally, patients
CC       may show dysarthria, nystagmus, spasticity of the lower limbs, and
CC       mild peripheral sensory neuropathy. {ECO:0000269|PubMed:24113144,
CC       ECO:0000269|PubMed:24312598, ECO:0000269|PubMed:24719489,
CC       ECO:0000269|PubMed:24742043, ECO:0000269|PubMed:25258038}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Antibodies against STUB1 are found in patients with
CC       chronic lymphocytic leukemia (CLL) and in colorectal cancer
CC       patients.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF039689; AAC18038.1; -; mRNA.
DR   EMBL; AF129085; AAD33400.1; -; mRNA.
DR   EMBL; AF432221; AAL99927.1; -; mRNA.
DR   EMBL; AF217968; AAG17211.1; -; mRNA.
DR   EMBL; AE006464; AAK61242.1; -; Genomic_DNA.
DR   EMBL; Z92544; CAM26348.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85758.1; -; Genomic_DNA.
DR   EMBL; BC007545; AAH07545.1; -; mRNA.
DR   EMBL; BC017178; AAH17178.1; -; mRNA.
DR   EMBL; BC022788; AAH22788.1; -; mRNA.
DR   EMBL; BC063617; AAH63617.1; -; mRNA.
DR   CCDS; CCDS10419.1; -. [Q9UNE7-1]
DR   CCDS; CCDS76797.1; -. [Q9UNE7-2]
DR   RefSeq; NP_001280126.1; NM_001293197.1. [Q9UNE7-2]
DR   RefSeq; NP_005852.2; NM_005861.3. [Q9UNE7-1]
DR   UniGene; Hs.592081; -.
DR   PDB; 4KBQ; X-ray; 2.91 A; A/B=21-154.
DR   PDBsum; 4KBQ; -.
DR   ProteinModelPortal; Q9UNE7; -.
DR   SMR; Q9UNE7; -.
DR   BioGrid; 115563; 262.
DR   DIP; DIP-29752N; -.
DR   IntAct; Q9UNE7; 143.
DR   MINT; MINT-1132706; -.
DR   STRING; 9606.ENSP00000219548; -.
DR   iPTMnet; Q9UNE7; -.
DR   PhosphoSitePlus; Q9UNE7; -.
DR   BioMuta; STUB1; -.
DR   DMDM; 78099173; -.
DR   EPD; Q9UNE7; -.
DR   PaxDb; Q9UNE7; -.
DR   PeptideAtlas; Q9UNE7; -.
DR   PRIDE; Q9UNE7; -.
DR   DNASU; 10273; -.
DR   Ensembl; ENST00000219548; ENSP00000219548; ENSG00000103266. [Q9UNE7-1]
DR   Ensembl; ENST00000564370; ENSP00000456875; ENSG00000103266. [Q9UNE7-2]
DR   Ensembl; ENST00000565677; ENSP00000457228; ENSG00000103266. [Q9UNE7-2]
DR   GeneID; 10273; -.
DR   KEGG; hsa:10273; -.
DR   UCSC; uc002cit.4; human. [Q9UNE7-1]
DR   CTD; 10273; -.
DR   DisGeNET; 10273; -.
DR   GeneCards; STUB1; -.
DR   H-InvDB; HIX0012661; -.
DR   HGNC; HGNC:11427; STUB1.
DR   HPA; CAB037202; -.
DR   HPA; CAB037209; -.
DR   HPA; HPA041222; -.
DR   HPA; HPA043531; -.
DR   MalaCards; STUB1; -.
DR   MIM; 607207; gene.
DR   MIM; 615768; phenotype.
DR   neXtProt; NX_Q9UNE7; -.
DR   OpenTargets; ENSG00000103266; -.
DR   Orphanet; 1173; Cerebellar ataxia - hypogonadism.
DR   PharmGKB; PA36227; -.
DR   eggNOG; KOG4642; Eukaryota.
DR   eggNOG; ENOG410ZC2R; LUCA.
DR   GeneTree; ENSGT00730000111218; -.
DR   HOGENOM; HOG000163725; -.
DR   HOVERGEN; HBG053046; -.
DR   InParanoid; Q9UNE7; -.
DR   KO; K09561; -.
DR   OMA; QENELHS; -.
DR   OrthoDB; EOG091G0FJB; -.
DR   PhylomeDB; Q9UNE7; -.
DR   TreeFam; TF313937; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q9UNE7; -.
DR   SIGNOR; Q9UNE7; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; STUB1; human.
DR   GeneWiki; STUB1; -.
DR   GenomeRNAi; 10273; -.
DR   PRO; PR:Q9UNE7; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000103266; -.
DR   CleanEx; HS_STUB1; -.
DR   ExpressionAtlas; Q9UNE7; baseline and differential.
DR   Genevisible; Q9UNE7; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0042405; C:nuclear inclusion body; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0031371; C:ubiquitin conjugating enzyme complex; TAS:HGNC.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0001664; F:G-protein coupled receptor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0030544; F:Hsp70 protein binding; IDA:HGNC.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:BHF-UCL.
DR   GO; GO:0019900; F:kinase binding; IPI:BHF-UCL.
DR   GO; GO:0051787; F:misfolded protein binding; IDA:BHF-UCL.
DR   GO; GO:0030674; F:protein binding, bridging; TAS:HGNC.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0030911; F:TPR domain binding; IDA:HGNC.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:1904264; F:ubiquitin protein ligase activity involved in ERAD pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; ISS:UniProtKB.
DR   GO; GO:0071218; P:cellular response to misfolded protein; IDA:BHF-UCL.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0006515; P:misfolded or incompletely synthesized protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0090035; P:positive regulation of chaperone-mediated protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:HGNC.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:HGNC.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0051604; P:protein maturation; TAS:HGNC.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:HGNC.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031943; P:regulation of glucocorticoid metabolic process; IDA:HGNC.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0030579; P:ubiquitin-dependent SMAD protein catabolic process; IDA:HGNC.
DR   Gene3D; 1.25.40.10; -; 2.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom.
DR   InterPro; IPR019734; TPR_repeat.
DR   InterPro; IPR003613; Ubox_domain.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF04564; U-box; 1.
DR   SMART; SM00028; TPR; 3.
DR   SMART; SM00504; Ubox; 1.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS50005; TPR; 3.
DR   PROSITE; PS50293; TPR_REGION; 1.
DR   PROSITE; PS51698; U_BOX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; DNA damage; DNA repair;
KW   Isopeptide bond; Neurodegeneration; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; TPR repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN         1    303       E3 ubiquitin-protein ligase CHIP.
FT                                /FTId=PRO_0000106329.
FT   REPEAT       26     59       TPR 1.
FT   REPEAT       60     93       TPR 2.
FT   REPEAT       95    127       TPR 3.
FT   DOMAIN      226    300       U-box.
FT   MOD_RES      19     19       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|Ref.9}.
FT   MOD_RES      23     23       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     149    149       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     273    273       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   CROSSLNK      2      2       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23560854}.
FT   CROSSLNK     22     22       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18042044}.
FT   CROSSLNK    221    221       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18042044}.
FT   CROSSLNK    255    255       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18042044}.
FT   VAR_SEQ       1     72       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15498874}.
FT                                /FTId=VSP_015947.
FT   VARIANT      28     28       E -> K (in SCAR16; reduces protein level;
FT                                does not reduce ubiquitin ligase activity
FT                                and autoubiquitination).
FT                                {ECO:0000269|PubMed:25258038}.
FT                                /FTId=VAR_072348.
FT   VARIANT      65     65       N -> S (in SCAR16; reduces protein level;
FT                                reduces ubiquitin ligase activity; does
FT                                not change autoubiquitination;
FT                                dbSNP:rs690016544).
FT                                {ECO:0000269|PubMed:25258038}.
FT                                /FTId=VAR_072349.
FT   VARIANT      79     79       A -> D (in SCAR16; dbSNP:rs587777347).
FT                                {ECO:0000269|PubMed:24742043}.
FT                                /FTId=VAR_071293.
FT   VARIANT      79     79       A -> T (in SCAR16; dbSNP:rs587777346).
FT                                {ECO:0000269|PubMed:24742043}.
FT                                /FTId=VAR_071294.
FT   VARIANT     123    123       L -> V (in SCAR16; dbSNP:rs587777344).
FT                                {ECO:0000269|PubMed:24742043}.
FT                                /FTId=VAR_071295.
FT   VARIANT     130    130       N -> I (in SCAR16; dbSNP:rs587777341).
FT                                {ECO:0000269|PubMed:24312598}.
FT                                /FTId=VAR_071296.
FT   VARIANT     145    145       K -> Q (in SCAR16; dbSNP:rs146251364).
FT                                {ECO:0000269|PubMed:24719489}.
FT                                /FTId=VAR_072350.
FT   VARIANT     147    147       W -> C (in SCAR16; dbSNP:rs587777342).
FT                                {ECO:0000269|PubMed:24312598}.
FT                                /FTId=VAR_071297.
FT   VARIANT     165    165       L -> F (in SCAR16; dbSNP:rs587777340).
FT                                {ECO:0000269|PubMed:24312598}.
FT                                /FTId=VAR_071298.
FT   VARIANT     236    236       S -> T (in SCAR16).
FT                                {ECO:0000269|PubMed:24312598}.
FT                                /FTId=VAR_071299.
FT   VARIANT     240    240       M -> T (in SCAR16; dbSNP:rs587777345).
FT                                {ECO:0000269|PubMed:24742043}.
FT                                /FTId=VAR_071300.
FT   VARIANT     246    246       T -> M (in SCAR16; inhibits ubiquitin
FT                                ligase activity and autoubiquitination;
FT                                dbSNP:rs587777343).
FT                                {ECO:0000269|PubMed:24113144,
FT                                ECO:0000269|PubMed:25258038}.
FT                                /FTId=VAR_071301.
FT   MUTAGEN      30     30       K->A: Loss of interaction with FOXP3 and
FT                                its ability to ubiquitinate FOXP3. Loss
FT                                of interaction with SMAD3, HSPA8,
FT                                HSP90AA1 and HSP90AB1.
FT                                {ECO:0000269|PubMed:23973223,
FT                                ECO:0000269|PubMed:24613385}.
FT   MUTAGEN     260    260       H->Q: Loss of ability to ubiquitinate
FT                                FOXP3. {ECO:0000269|PubMed:23973223}.
FT   MUTAGEN     269    269       P->A: Abolishes E3 ligase activity.
FT                                {ECO:0000269|PubMed:23990462}.
FT   CONFLICT     52     52       A -> V (in Ref. 2; AAD33400).
FT                                {ECO:0000305}.
FT   CONFLICT    272    272       R -> G (in Ref. 1; AAC18038).
FT                                {ECO:0000305}.
FT   CONFLICT    280    280       L -> F (in Ref. 1; AAC18038).
FT                                {ECO:0000305}.
FT   HELIX        26     38       {ECO:0000244|PDB:4KBQ}.
FT   HELIX        42     55       {ECO:0000244|PDB:4KBQ}.
FT   HELIX        60     72       {ECO:0000244|PDB:4KBQ}.
FT   HELIX        76     89       {ECO:0000244|PDB:4KBQ}.
FT   HELIX        94    106       {ECO:0000244|PDB:4KBQ}.
FT   HELIX       110    126       {ECO:0000244|PDB:4KBQ}.
FT   HELIX       134    147       {ECO:0000244|PDB:4KBQ}.
FT   TURN        148    151       {ECO:0000244|PDB:4KBQ}.
SQ   SEQUENCE   303 AA;  34856 MW;  7E7D6568B17070BF CRC64;
     MKGKEEKEGG ARLGAGGGSP EKSPSAQELK EQGNRLFVGR KYPEAAACYG RAITRNPLVA
     VYYTNRALCY LKMQQHEQAL ADCRRALELD GQSVKAHFFL GQCQLEMESY DEAIANLQRA
     YSLAKEQRLN FGDDIPSALR IAKKKRWNSI EERRIHQESE LHSYLSRLIA AERERELEEC
     QRNHEGDEDD SHVRAQQACI EAKHDKYMAD MDELFSQVDE KRKKRDIPDY LCGKISFELM
     REPCITPSGI TYDRKDIEEH LQRVGHFDPV TRSPLTQEQL IPNLAMKEVI DAFISENGWV
     EDY
//
